Grant of Options

RNS Number : 5119V

BiVictriX Therapeutics PLC

14 December 2021

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Grant of Options

Alderley Park, 14 December 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces that on 13 December 2021 it granted options to employees for an aggregate 876,333 ordinary shares of 1 pence each ("Options"). 

The Options have been granted pursuant to the terms of the Company's Enterprise Management Incentive Scheme, which was implemented in August 2021, in conjunction with the Company's Admission to trading on AIM.

All Options are subject to continuous employment and are exercisable up to 10 years from the date of being granted. The Options have an exercise price of 25 pence, this being the closing market price on 13 December 2021, and vest over three years. Of the Options, 816,334 were granted to Oliver Schon, VP Product Development & CMC, of which 408,167 are exercisable upon him meeting specific R&D goals.

Following this grant, the total number of ordinary shares under option is 8,614,183.

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.

**Ends**

For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman  Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker) Tel: [phone] David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker) Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl Consilium Strategic Communications Ashley Tapp, Suki Virji Tel: [phone] Email:  [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at  www.bivictrix.com .

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Oliver Schon
2.	Reason for the Notification
a)	Position/status	VP Product Development & CMC
b)	Initial notification/Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	BiVictriX Therapeutics plc
b)	LEI	213800ZI85IZNA6N3L53
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Options over Ordinary Shares of 1 pence each GB00BNXH3K91
	Identification code
b)	Nature of the transactions	Grant of Options
c)	Price(s) and volume(s)	Price(s) Volume(s) 25 pence 816,334
d)	Aggregated information: -     Aggregated volume -     Price	Price(s) Volume(s)  25 pence 816,334
e)	Date of the transactions	13 December 2021
f)	Place of the transactions	Outside a trading venue

 

END

 

 

DSHDBBDDCDBDGBX